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Abstract: In 1996 a meta-analysis was published showing that an increase in plasma triglyceride (TG) levels was 
associated with an increase in CHD risk, even after adjustment for high density lipoprotein cholesterol (HDL-C) levels. 
Very recently, two studies were published that further extent the early observation and showed the importance of 
nonfasting plasma triglyceride (TG) levels in the prediction of risk on coronary heart disease (CHD). In the current review 
we have summarized all available evidence obtained in clinical studies showing that treatment guidelines should 
reconsider to include nonfasting TG in their risk assessments as nonfasting TG levels may better predict CVD risk.  
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INTRODUCTION 
  Despite the introduction of a plethora of pharmacological 
and other modalities, cardiovascular disease (CVD) is still a 
principal cause of morbidity and mortality in Western 
society [1]. The use of HMG-CoA inhibitors (statins) have 
led to impressive reductions in low-density lipoprotein 
cholesterol levels (LDL-C). However, only moderate reduc-
tions in total mortality were achieved. As a result, current 
therapeutic guidelines advocate a more stringent LDL-C 
target in patients at very high or high risk. Since the majority 
of patients who are currently seen at out-patient clinics 
display a different lipid phenotype than in the past, the 
guideline committees have added non-high density 
Lipoprotein cholesterol (non-HDL-C) as a secondary goal 
for those with TG levels above 200 mg/dL (1.5 mmol/L) [2-
4]. Worldwide, the general population is becoming more 
obese. This leads to an increase in the prevalence of the so-
called atherogenic lipoprotein profile with increased levels of 
non-HDL-C, apolipoprotein (apo)B, TG as well as decreased 
levels of HDL-C. Moreover, an increased prevalence of 
small dense LDL particles is observed. The purpose of the 
current review is to assess all evidence showing that both TG 
and non-HDL-C, a marker reflecting both atherogenic LDL 
and very low density lipoprotein (VLDL) particles, are 
independent risk factors for CVD. 
TRIGLYCERIDE METABOLISM (FIG. 1) 
  Plasma TG are derived from dietary sources as well as 
from de novo TG synthesis [5]. During its path through the 
digestive system, dietary fat is readily lipolysed, dissolved 
into micelles and finally hydrolysed by pancreatic lipase, 
thereby enabling the uptake of fatty acids in the small 
intestine [6]. Upon its entry into the enterocyte fatty acids 
will be converted into TG by the enzyme acyl-CoA:diacyl-
glycerol acyltransferase 2 (DGAT2)[7]. TG can be stored in 
lipid droplets but most of the TG will be packed in apoB-48-
containing lipoprotein particles (chylomicrons) by micro- 
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somal triglyceride transfer protein (MTTP) and subsequently 
secreted in the lymphatic system which directly drains into 
the systemic circulation bypassing the liver [8].  
  De novo lipogenesis occurs in the liver. Released fatty 
acids from adipose tissue, the TG storage pool in the human 
body, are directly taken up by the liver and can be consi-
dered as major source for substrate. The liver exclusively 
synthesizes apoB-100 containing VLDL particles. There are 
large similarities between the processing of apoB-48-
containing chylomicron particles in the enterocytes and 
apoB-100-containing VLDL particles in the liver involving 
DGATs and MTP. The liver synthesizes a TG-poor VLDL 
particle (VLDL2) [9]. VLDL2 can either be secreted by the 
hepatocyte or further lipidated to form a mature, triglyceride-
rich VLDL (VLDL1) [10]. VLDL assembly is dependent on 
the accumulation of TG in the liver, and it has been 
suggested that the fatty acids used for the biosynthesis of 
VLDL-TG are derived predominantly from TG stored in 
cytosolic lipid droplets [10].
  Upon secretion, TGs are directly lipolysed by lipoprotein 
lipase (LPL) present in the capillary beds of adipose tissue 
and skeletal muscle. ApoC-II acts as an important co-factor. 
Of note, patients deficient in apoC-II have severe hypertri-
glyceridemia [11]. A number of different proteins such as 
apoC-III, apoA-V, angiopoietin-like proteins ANGPTL 3 
and 4 are also present in the circulation and may act as 
potential inhibitors for the action of LpL [12]. The released 
fatty acids can subsequently be taken up by the adipose 
tissue for energy storage and by skeletal muscle where they 
can be directly used for energy. In the heart, LPL-derived 
fatty acids are responsible for up to 70% of the energy 
source [13]. The remaining apoB-48 containing chylomicron 
remnants will be directly taken up by the liver through a 
concerted action of heparin sulphate proteoglycans (HSPG), 
which can rapidly bind apoB-48, LDL receptor-related 
protein 1 (LRP1) and by the LDL-receptor located on the 
plasma membrane that will bind apoE present on the 
chylomicron remnant particle [7, 14, 15]. Further modulation 
of apoB-100-containing VLDL remnant particles, mediated 
by the action of LpL, hepatic lipase (HL) and cholesteryl 
ester transfer protein (CETP), will eventually lead to the 
formation of a cholesterol-enriched LDL particle that is   Triglycerides and Cardiovascular Risk  Current Cardiology Reviews, 2009, Vol. 5, No. 3    217
Fig. (1). Lipoprotein metabolism in the insulin resistance state. 
In the insulin resistance state (IR) an enhanced lipolysis in adipocytes, due to increased HSL activity while ATGL activity is normal, results 
in an increased supply of FFA to the liver which will subsequently lead to increased hepatic TG storage. As a consequence VLDL production 
and secretion is increased and LPL activity may be reduced. Increased amounts of TG-rich lipoproteins result in an enhanced formation of 
small dense LDL particles, due to enhanced activity of CETP mediated exchange of cholesteryl esters and TG between HDL and TG-rich 
lipoproteins. TG-enriched HDL particles may be modulated by hepatic lipase (HL) resulting in smaller–sized HDL3 particles which will be 
rapidly cleared and explains the decrease in plasma HDL-C. Scavenger receptor B1 (SR-B1) may be involved in the hepatic clearance of 
HDL-cholesteryl esters. There may be a delay in clearance of LDL particles due to decreased expression of the LDL receptor. 
Abbreviations: IR insulin resistance; apo, apolipoprotein; FFA, free fatty acids; CETP cholesteryl ester transfer protein, HL hepatic lipase;
ATGL adipose tissue triglyceride lipase; HSL hormone sensitive lipase; MTP microsomal triglyceride transfer protein; SR-B1 scavenger 
receptor B1. 
This figure is adopted from Westerveld H.E. et al. [58] and published with permission of Elsevier. 218 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Harchaoui et al. 
finally cleared by hepatic LDL receptors. TGs are water-
insoluble and are thus located in the core of the particle. A 
decrease in the TG content of the particle leads to shrinking 
of the particle and subsequently abundant phospholipid-rich 
surface material will contribute to the formation of lipid-poor
apoA-I enriched pre- HDL particles, mediated by phos-
pholipid transfer protein (PLTP) [16]. CETP and PLTP 
activities will increase in the presence of an increased pool 
of TG-rich lipoprotein particles and may therefore contribute 
to decreased HDL-C levels and an increased concentration of 
atherogenic small dense LDL in hypertriglyceridemic 
conditions [17]. 
  Hypertriglyceridemia is often observed in patients with 
the metabolic syndrome (MetS), type 2 diabetes (DM) or 
familial combined hyperlipidemia (FCHL) [18, 19]. The 
hallmark of these clinical phenotypes is the presence of 
insulin resistance [10]. Insulin plays an important role in the 
regulation of lipid homeostasis. In the insulin resistant state, 
the normal response to insulin is attenuated. This will 
eventually lead to abnormalities in lipid handling in those 
organs that are particularly sensitive to insulin regulation 
such as adipose tissue, liver and skeletal muscle. In the fed 
state, insulin activates LPL in adipose tissue and thereby set 
the switch to uptake of free fatty acids (FFA) into the 
adipocytes which will then be stored in lipid droplets. In the 
fasted state, when insulin levels are low, glucagon will 
upregulate hormone sensitive lipase (HSL) by inactivation of 
cAMP mediated PKA-dependent phosphorylation of HSL 
thereby enabling the formation of FFA which are secreted 
and taken up by peripheral tissues [20]. Adipose tissue 
triglyceride lipase (ATGL), an enzyme that is involved in the 
first step of TG hydrolysis may act independent of hormonal 
activation [20]. In the liver, increased FA supply, due to 
adipose tissue insulin resistance, leads to abnormal VLDL 
synthesis and secretion through the enhanced TG pool in the 
liver [10]. It has since long been recognized that fatty acids 
are important ligands for several nuclear receptors that 
control lipid metabolism [21]. Abnormal signalling, as 
observed in the insulin resistant state, therefore contributes 
extensively to the up-regulation in hepatic lipoprotein 
assembly seen in hypertriglyceridemia.  
TG AND CVD RISK
  Hokanson and Austin already showed in 1996 in a meta 
analysis that TG are an independent risk factor for CVD 
[22]. Presence of elevated concentrations of atherogenic TG-
rich remnant lipoproteins is the principle abnormality 
responsible for this association [23]. However, the evidence 
for TG being an independent risk factor for CHD remains to 
some extent controversial because data obtained in large 
clinical studies were not always equivocal. Moreover, in the 
case of positive findings, the effect sizes were very modest. 
A number of issues have been raised to explain these 
inconclu-sive results. Plasma TG are a highly variable lipid 
compo-nent, as it reflects the daily consumption of dietary 
fat. Nowadays humans consume at least three consecutive 
meals per day. As a consequence, people are in a continuous 
post-prandial state which is reflected in highly variable 
plasma TG levels [24]. Secondly, patients with high TG 
levels frequently exhibit additional risk factors, such as 
insulin resistance that may affect their susceptibility to 
athero-sclerosis. Finally, elevated plasma TG levels are 
strongly associated with low HDL-C levels [25]. In 
prospective epidemiological studies it will thus be difficult to 
separate the contributions of HDL and TG to atherosclerosis 
suscep-tibility. Based on these limitations, investigators have 
argued that maybe non-HDL-C would be a better marker to 
explain the whole spectrum of atherogenic lipoprotein 
particles including LDL, small dense LDL and VLDL 
remnants. Indeed a recent post hoc analysis was performed 
using combined data of the ‘Treating to New Targets’-TNT 
trial and the ‘Incremental Decrease in End Points through 
Aggressive Lipid Lowering’-IDEAL trial and it revealed that 
on-treatment levels of non-HDL-C but also apoB were more 
closely associated with cardiovascular outcome than LDL-C 
or total cholesterol levels [26].  
  A number of population studies have investigated 
whether plasma TG are an independent risk factor for CVD. 
The Prospective Cardiovascular Münster (PROCAM) study 
involved 4849 middle-aged men who were followed up for 8 
years to record the incidence of coronary heart disease 
(CHD) events according to the risk factors present at study 
entry. The study showed that fasting levels of TG were an 
independent risk factor for CHD events, independent of 
serum levels of HDL-C or LDL-C [27]. In the 8-year 
Copenhagen Male Study [28], a prospective study including 
2906 men who were free of cardiovascular disease at 
baseline, the risk for ischemic heart disease was 50% higher 
in those with TG levels in the middle tertile and 120% higher 
in the upper tertile as compared to those in the lowest TG 
tertile after adjustment for conventional risk factors such as 
age, body mass index (BMI), alcohol intake, smoking, 
physical activity, hypertension, diabetes, and LDL-C and 
HDL-C levels. A number of meta-analyses have been 
published showing independent associations between TG 
levels and CHD risk, independent of HDL-C levels [22, 29, 
30]. A relative risk of 1.32 (95%CI 1.26-1.39) in men and 
1.76 (95% CI 1.50-2.07) in women was originally found 
[31]. More recent analyses in individuals selected from the 
Reykjavik cohort and the Epic-Norfolk cohort revealed an 
odds ratio for CHD of 1.76 in the former and 1.57 in the 
latter when comparing individuals in the lowest tertile for 
TG as compared to those in the highest tertile, which was 
similar to data derived from a meta-analysis [30]. In line 
with these results are the data derived in a study of 13,953 
young men for which Tirosh et al. [32] reported on an 
association between the first of 2 TG measurements obtained 
5 years apart with incident CHD. After an average follow-up 
of 10.5 years, men in the fifth quintile of TG, compared with 
those in the lowest quintile, had a multivariable hazard ratio 
for CHD of 4.1. Additionally, it has been reported that in 
patients with CHD TG levels were significantly related to 
secondary CVD events independent of HDL-C and LDL-C 
with a HR of 1.50 [33]. 
  Recently, the debate has arisen focused on fasting versus 
non-fasting plasma TG. Two publications showed a strong 
association between non-fasting plasma TG and CVD risk 
[24, 34-36]. In the Copenhagen City Heart Study which 
included 19,329 men and women with an average follow up 
of 26 years, nonfasting TG levels were associated with 
increased risk of myocardial infarction, ischemic heart 
disease and death. An expansion of this study was recently 
published where they studied 33,391 inhabitants of 
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which comprised 26,509 women, nonfasting TG levels were 
associated with incident cardiovascular events, independent 
of traditional cardiac risk factors, levels of other lipids, and 
markers of insulin resistance. Recently, data obtained from a 
prospective study in 26,330 healthy women, revealed that the 
association with CVD was stronger for nonfasting TG 
compared with fasting measurements of TG [24]. All these 
observations combined suggest that nonfasting TG measure-
ments reflect more accurately the presence of atherogenic 
remnant lipoproteins. 
  As mentioned above, elevated plasma TG levels are 
frequently observed in conditions which share a similar 
Table 1. TG as an Independent Marker for Atherosclerosis in Patients with Metabolic Syndrome, type 2 Diabetes and Familial 
Combined Hyperlipidemia. Articles are Presented by Publication Date, Starting with the most Recent Published Data 
Article 
No. of 
Patients 
Included in 
the Study 
Population  Age 
(y)  F/U  TG levels 
mg/dL  Outcome  Relative 
Risk*  Comment 
Giorda  
et al. [52] 
844men and 
women 
Type 2 diabetes 
without CVD 
40-97  4 year  > 150 mg/dL  CVD  HR: 1.93 
(1.10-3.40) 
multivariate analyses 
Nilsson 
et al. [45] 
5,047 men and 
women 
non-diabetics 
with MetS  57.5  11 years 
fatal + 
nonfatal 
CVD 
HR:1.37 (1.09-
1.73) 
HR for MetS: 
MetS NCEP-ATPII: 1.95 
(1.56-2.43) 
MetS EGIR: 1.55 (1.23-
1.95) 
MetS IDF 1.37 (1.09-
1.72) 
Kadota  
et al. [46] 
7,219 men and 
women 
MetS  >30 9.6 year  CVD 
mortality 
1.42 (0.95-
2.11) 
multivariate analyses 
Avogaro 
et al. [51] 
6,032 women 
and 5,612 men 
Type 2 diabetes 
without CVD 
64-68  4 years  > 150 mg/dL  First CHD 
event 
HR: men 1.19 
(0.96-1.12) 
women 1.33 
(1.05-1.68) 
Onat  
et al. [47] 
1,277 men and 
1,405 women  MetS  43±15  Population 
based 
138 mg/dL for 
men and 121 
mg/dL for 
women 
CVD  HR 1.4 in men 
Schulze 
et al. [55]  921 women  Type 2 diabetes  30-55  10
307 mg/dL 
(median 
highest 
quartile) 
CHD  1.42 (0.79-
2.54)  multivariate analysis 
Ninomiya 
et al. [44] 
15,922 men 
and women 
MetS 
(NHANESIII 
study) 
20-89  MI/stroke  OR 1.66 (1.20- 
2.30) 
OR for MetS 
2.01 (1.53-2.64) 
Lu et al. 
[54] 
2,108 men and 
women  Type 2 diabetes  45-74  9 > 176 mg/dL  CVD 
men: 1.39 
(1.00-1.98) 
women: 1.61 
(1.17-2.22) 
HR for the highest tertile 
of non-hdl in men and 
women with diabetes 
(2.23 and 1.80) was 
higher than for TG. 
Austin  
et al. [56] 
264 men and 
women 
FCH  46 20 year  202 mg/dL  CVD 
mortality 
RR 1.5 (0.87-
2.4) 
adjusted RR 
Laakso, 
et al. [53] 
313 men and 
women  Type 2 diabetes  57al  7 > 205 mg/dL 
CHD death 
all CHD 
events 
OR 2.2 (1.2-
4.0) for CHD 
death 
1.6 (1.0-2.8) 
all CHD 
events 
age adjusted odds ratios 
Hopkins, 
et al. [57] 
333 cases and 
1,743 controls 
man and 
women 
FCH  61 population 
based study 
188 mg/dL  CAD 
OR FCH and 
CAD 
unadjusted: 
1.86 (1.18-
2.93) 
adjusted for 
TG 0.97 (0.59-
1.60) 
CAD risk associated 
with FCH is dependent 
on triglyceride levels 
HR = Hazard ratio  OR = Odds ratio  FCH = Familial combined hyperlipidemia  CVD = Coronary vascular disease 
RR= Relative risk  MetS = Metabolic Syndrome  MI = Myocardial infarction  CHD = Coronary heart disease 220 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Harchaoui et al. 
metabolic background, such as type 2 diabetes [18], the 
metabolic syndrome [37] and familial combined hyperli-
pidemia FCHL [38]. A central hallmark is the presence of 
insulin resistance. Such patients share the presence of the 
atherogenic lipoprotein phenotype being increased plasma 
TG, decreased HDL-C and increased prevalence of small 
dense LDL particles. Thus the combination of increased 
hepatic VLDL secretion, and impaired LPL-mediated TG 
clearance in combination with abnormal function of lipid 
transfer proteins explains the hypertriglyceridemia pheno-
type. Consequently, central insulin resistance is the underl-
ying pathophysiological abnormality contributing to periphe-
ral hypertriglyceridemia. In the next paragraphs we will 
summarize the available evidence that plasma TG are 
associated with CVD risk in these conditions. As a basis, we 
have used a pubmed search based on the keywords: TG, 
metabolic syndrome (MetS), familial combined hyperlipi-
demia (FCHL), type 2 diabetes (DM), and CVD risk. 
Moreover, we only used those articles published within the 
last 10 years. In total we have selected 11 articles that met 
our inclusion criteria, of which one was published in 1993 
and the others were published in 2000 or later (Table 1). 
TG AND CVD RISK IN TYPE 2 DIABETES, 
METABOLIC SYNDROME AND FAMILIAL 
COMBINED HYPERLIPIDEMIA (TABLE 1) 
  MetS is defined as the presence of a cluster of risk factors 
including: waist circumference > 102 cm in men or > 88 cm 
in women, fasting serum TG > 150 mg/dL; blood pressure > 
130/85mmHg; HDL < 40 mg/dL in men or < 50 mg/dL in 
women and fasting serum glucose > 110 mg/dL [39-41]. 
Individuals that have at least three out of the five criteria are 
diagnosed as having MetS. As a consequence MetS popula-
tion studies have to deal with a large heterogeneity which 
may lead to underestimation of the risk factor estimation. 
Yet, a large number of population studies have been 
published using the above described inclusion criteria. 
Several studies have shown that presence of the MetS or 
diabetes is associated with increased CVD risk. In the 
European DECODE (Diabetes Epidemiology: Collaborative 
Analysis Of Diagnostic Criteria in Europe) study, non-
diabetics with MetS had an increased risk of all cause 
mortality (men: 1.4; women: 1.38) as well as from CVD 
(men: 2.26; women: 2.78) [42]. In a prospective cohort 
study, Lakka et al. found that men with the metabolic 
syndrome were at greater risk of cardiovascular disease 
(CVD) and all-cause mortality, even in the absence of 
baseline CVD and diabetes [43]. The question whether 
plasma TG may be considered as an independent risk factor 
for the prediction of CVD is only addressed in a small 
number of studies as summarized in Table 1. Because MetS 
is not a single entity but consists of a cluster of cardio-
vascular risk factors it is difficult to show whether TG are 
independently associated with CVD in these studies. Studies 
that included analyses of prediction of CVD based on the 
MetS and TG showed comparable risk ratio’s for MetS and 
TG [44-47]. Thus, recognition of the syndrome is important 
because people with metabolic syndrome are more likely to 
die from coronary heart disease or stroke compared with 
people without the syndrome [48]. More importantly patients 
with MetS are prone to develop type 2 diabetes and 
subsequently CVD [49]. 
  Patients with diabetes have lower HDL-C and higher TG 
concentrations. Data from the Framingham Heart Study [50] 
show that twice as many diabetic than non-diabetic indivi-
duals have low plasma levels of HDL-C and elevated TG 
The strong inverse relationship between TG and HDL-C 
hampers the assessment of the attributable risk of TG and 
CVD in diabetes. In patients with diabetes mellitus plasma 
TG concentration was significantly associated with CVD in 
univariate analyses in several studies [51-55]. However, the 
independent association of TG with CVD disappeared in 
most studies when other lipid risk factors, especially HDL-C 
levels, were taken into account. Interestingly non-HDL-C 
appears to be a better predictor of CVD risk in diabetes in 
the presence of high TG levels [54, 55]. Only two studies 
were published addressing the question whether plasma TG 
is a major independent risk factor in FCHL [56, 57]. The 
observed relative risk was similar to that of type 2 diabetes 
and MetS. 
CONCLUSIONS 
  Epidemiological evidence indicates that plasma TG 
levels predict CVD. The independent relationship between 
TG and CHD is more consistently observed in the general 
population. In patients with the MetS or diabetes, who share 
a common metabolic background, plasma TG appear as 
independent predictors of CVD risk, but the data are incon-
sistent. The strong inverse relationship between TG and 
HDL-C in these patients may reflect a common pathophysio-
logic process and hampers the statistical analyses. For CVD 
risk estimation and subsequently therapeutic interventions it 
is therefore recommended to take into account both high TG 
and low HDL-C levels. Accumulating evidence shows that 
nonfasting TG levels may better predict CVD risk. Treat-
ment guidelines should reconsider to include nonfasting TG 
in their risk assessments.  
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